Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 14th May 2013 08:04

Babcock International: Jefferies increases target price from 1080p to 1250p and maintains a buy recommendation.Barratt Developments: Bank of America takes target price from 265p to 325p, while downgrading to neutral.Belgravium Technologies: WH Ireland places both its target price and its neutral rating under review.Bellway: Bank of America ups target price from 1135p to 1440p, while its neutral rating remains unchanged.Berkeley Group: Bank of America moves target price from 2183p to 2495p and retains a buy recommendation.Betfair Group: Investec increases target price from 585p to 750p, but still recommends selling.Blinkx: Citigroup ups target price from 115p to 130p and reiterates a buy recommendation.Bovis Homes Group: Bank of America increases target price from 695p to 800p, while downgrading to neutral.British Land: Panmure Gordon increases target price from 600p to 630p, while downgrading from buy to hold. Investec downgrades from buy to reduce with a target price of 600p.Capita: Panmure Gordon raises target price from 740p to 850p, but still recommends selling.Cranswick: Investec ups target price from 1095p to 1180p and retains a buy recommendation.Daily Mail & General Trust: Deutsche Bank revises target price from 630p to 660p and keeps a hold recommendation.Diploma: Jefferies raises target price from 615p to 690p and reiterates a buy recommendation.e-Therapeutics: Panmure Gordon shifts target price from 67p to 70p and stays with its buy recommendation.Halfords Group: N+1 Singer ups target price from 390p to 440p keeping a buy recommendation.Heritage Oil: Canaccord Genuity reduces target price from 350p to 300p, while reiterating its buy recommendation.Howden Joinery: Jefferies lowers target price from 200p to 186p and downgrades to underperform.ICAP: Canaccord Genuity upgrades from sell to hold with a target price of 300p.Imagination Technologies Group: Liberum Capital cuts target price from 415p to 330p keeping a hold recommendation.IMI: Investec takes target price from 1295p to 1355p, while its hold recommendation is reiterated.Interserve: JP Morgan shifts target price from 532p to 533p and keeps an overweight rating.Jarvis Securities: WH Ireland increases target price from 300p to 320p retaining a buy recommendation.Johnston Press: Panmure Gordon shifts target price from 20p to 25p, while leaving its buy recommendation unaltered.Laird: Espirito Santo reduces target price from 300p to 265p, while its buy recommendation is maintained.Lonmin: Westhouse Securities ups target price from 235p to 250p, but still recommends selling. Deutsche Bank takes target price from 365p to 395p, while staying with its hold recommendation.Man Group: Espirito Santo ups target price from 76p to 87p, but still recommends selling.Marks & Spencer: Panmure Gordon increases target price from 402p to 471p and keeps its buy recommendation.Mitchells & Butlers: Numis takes target price from 400p to 450p retaining an buy recommendation.Mothercare: N+1 Singer raises target price from 380p to 400p staying with its buy recommendation.Nature Group: WH Ireland shifts target price from 42p to 50p and reiterates its buy recommendation.Persimmon: Bank of America raises target price from 1120p to 1175p keeping its buy recommendation.Petropavlovsk: Westhouse Securities increases target price from 250p to 285p and stays with its buy recommendation. JP Morgan shifts target price from 420p to 430p retaining an overweight rating. Numis shifts target price from 290p to 300p and leaves its buy recommendation unaltered.Premier Oil: Deutsche Bank cuts target price from 615p to 600p leaving its buy recommendation unchanged.Rathbone Brothers: Canaccord Genuity downgrades from buy to hold with a target price of 1500p.Redrow: Bank of America revises target price from 220p to 300p maintaining a buy recommendation.Rio Tinto: UBS cuts target price from 4590p to 4550p and stays with its buy recommendation.SIG: Jefferies shifts target price from 185p to 190p keeping a buy recommendation.Smith & Nephew: Berenberg shifts target price from 805p to 810p, while downgrading from buy to hold. Investec revises target price from 755p to 776p and stays with its add recommendation.Standard Chartered: Citigroup reduces target price from 1900p to 1775p, while its buy recommendation remains unaltered.St. James's Place: Credit Suisse ups target price from 520p to 600p and reiterates a neutral rating.Taylor Wimpey: Bank of America moves target price from 75p to 115p upgrading to buy.Travis Perkins: Jefferies lowers target price from 1130p to 1120p downgrading to underperform.TUI Travel: Jefferies ups target price from 300p to 315p reiterating its hold recommendation. JP Morgan shifts target price from 350p to 360p, while downgrading to neutral.Wetherspoon (JD): Investec takes target price from 550p to 660p and maintains a buy recommendation.Wolseley: Jefferies moves target price from 2540p to 2520p and leaves its underperform recommendation unchanged.
More News
16 Oct 2013 11:57

UK WINNERS & LOSERS: Hargreaves Continues To Rise, e-Therapeutics Trips

Read more
16 Oct 2013 08:56

e-Therapeutics Pretax Loss Widens As R&D Expenditure Rises

Read more
30 Sep 2013 18:45

DIRECTOR DEALINGS: E-Therapeutics Exec, Wife Combined Shares Total 1.8M

Read more
24 Jul 2013 15:53

Wife of DS Smith CEO sells 5.6m-pound stake

The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year. The move came on Tuesday, the same day DS Smith released its annual report

Read more
14 May 2013 09:46

e-Therapeutics pleases with pipeline progress

News from biotech company e-Therapeutics about the progress of two clinical trials for its cancer drug pleased the markets on Tuesday. The AIM-listed company provided first findings for the company's ETS2101 drug candidate in Phase I trials in the US for patients with brain cancer and in the UK fo

Read more
10 May 2013 07:14

Friday broker round-up UPDATE

Afren: Westhouse Securities initiates with a target price of 160p and a buy recommendation. Ashmore Group: Credit Suisse raises target price from 375p to 440p upgrading from underperform to neutral. Barratt Developments: Citigroup increases target price from 245p to 315p leaving its neutral rating

Read more
19 Feb 2013 16:21

Debenhams Executive Director adds to stake

Michael Sharp, the Executive Director of retail chain Debenhams, has topped up his stake in the group with the purchase of 50,000 shares. Sharp, who has been in his current role since September 2011, bought the shares at 97.20p for a total of £48,598. He now holds 6.2m shares in the company. Debe

Read more
11 Feb 2013 09:15

e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday. Following the proposed issu

Read more
23 Oct 2012 09:23

Tuesday broker round-up

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe

Read more
22 Oct 2012 08:19

Monday broker round-up - UPDATE

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl

Read more
22 Oct 2012 07:53

e-therapeutics produces mixed interims

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug. As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business. The company ha

Read more
15 Mar 2011 17:05

Bramson vehicle buys more shares in F&C

F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new di

Read more
14 Mar 2011 17:19

Wife of outgoing FD sells British Land shares

Diane Roberts, the wife of British Land finance director Graham Roberts, has raised more than £1m by selling more than three-quarters of the couple's stake in the property investor. She sold 191,780 shares at 562.8p each, which raised £1.08m. The couple are left with 50,464 shares in British Land.

Read more
4 Mar 2011 17:03

Shaftesbury boss invests £100,000

Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares la

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.